Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POTENTIA phase 1 trial of CB307 in PSMA-positive advanced or metastatic solid tumors
NL-OMON52294Phase 1Completed
- Sponsor
- Crescendo Biologics
- Start
- Oct 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 89Zr-CB307 in Nonhematologic neoplasms, prostate cancer (PCa), non-small cell lung cancer (NSCLC) and 4 more, sponsored by Crescendo Biologics. Primary endpoints: Dose-limiting toxicities and Safety and tolerability. Started Oct 2021; status: completed.
02
Drugs
89Zr-CB307
03
Conditions
Nonhematologic neoplasmsprostate cancer (PCa)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON52294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52294.